Tangeretin, a citrus pentamethoxyflavone, exerts cytostatic effect via p53/p21 up-regulation and suppresses metastasis in 7,12-dimethylbenz(α)anthracene-induced rat mammary carcinoma

Journal of Nutritional Biochemistry

Volumn 25, Issue 11, 2014, Pages 1140-1153

  Arivazhagan, Lakshmi ^a   Sorimuthu Pillai, Subramanian ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Breast cancer; Chemotherapeutic agent; DMBA; G1 S arrest; Metastasis; Tangeretin

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARBONYL DERIVATIVE; COLLAGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLOOXYGENASE 2; ESTRADIOL; GELATINASE A; GELATINASE B; GLYCOPROTEIN; KI 67 ANTIGEN; LIPID; NITRIC OXIDE; PROGESTERONE; PROLACTIN; PROTEIN; PROTEIN P21; PROTEIN P53; PROTEIN PCNA; SIALIC ACID; TANGERETIN; UNCLASSIFIED DRUG; VASCULOTROPIN; CARCINOGEN; FLAVONE DERIVATIVE; SEX HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME NOR; CONTROLLED STUDY; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; HISTOCHEMISTRY; HISTOLOGY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; MAMMARY GLAND; MAST CELL; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STAINING; TISSUE LEVEL; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; EXPERIMENTAL MAMMARY NEOPLASM; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; WISTAR RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BODY WEIGHT; CARCINOGENS; FEMALE; FLAVONES; GONADAL STEROID HORMONES; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RATS, WISTAR; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84908242006     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.06.007     Document Type: Article

References (60)

1. Jemal A., Bray F., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Datta K., Choudhuri M., Guha S., Biswas J. Breast cancer scenario in a regional cancer centre in Eastern India over eight years - still a major public health problem. Asian Pac J Cancer Prev 2012, 13(3):809-813.
3. McPherson K., Steel C.M., Dixon J.M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000, 321(7261):624-628.
4. Michor F., Iwasa Y., Nowak M.A. Dynamics of cancer progression. Nat Rev Cancer 2004, 4(3):197-205.
5. Koumoutsakos P., Pivkin I., Milde F. The fluid mechanics of cancer and its therapy. Annu Rev Fluid Mech 2013, 45:325-355.
6. Costa I., Solanas M., Escrich E. Histopathologic characterization of mammary neoplastic lesions induced with 7, 12 dimethylbenz(α)anthracene in the rat: a comparative analysis with human breast tumors. Arch Pathol Lab Med 2002, 126(8):915-927.
7. Anderson W.A., Perotti M.E., McManaway M., Lindsey S., Eckberg W.R. Similarities and differences in the ultrastructure of two hormone-dependent and one independent human breast carcinoma grown in athymic nude mice: comparison with the rat DMBA-induced tumor and normal secretory mammocytes. J Submicrosc Cytol 1984, 16(4):673-690.
8. Russo J., Tait I., Russo I.H. Susceptibility of the mammary gland to carcinogenesis. III. The cell of origin of rat mammary carcinoma. Am J Pathol 1983, 113(1):50-66.
9. Beecher G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 2003, 133(10):3248S-3254S.
10. Rice-Evans C.A., Miller N.J., Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996, 20(7):933-956.
11. Zhu Y., Mao Y., Chen H., Lin Y., Hu Z., Wu J., et al. Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int 2013, 13(1):54.
12. Kawaii S., Tomono Y., Katase E., Ogawa K., Yano M. Quantitation of flavonoid constituents in citrus fruits. J Agric Food Chem 1999, 47(9):3565-3571.
13. Chaumontet C., Bex V., Gaillard-Sanchez I., Seillan-Heberden C., Suschetet M., Martel P. Apigenin and tangeretin enhance gap junctional intercellular communication in rat liver epithelial cells. Carcinogenesis 1994, 15(10):2325-2330.
14. Pan M.H., Chen W.J., Lin-Shiau S.Y., Ho C.T., Lin J.K. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 2002, 23(10):1677-1684.
15. Seo J., Lee H.S., Ryoo S., Seo J.H., Min B.S., Lee J.H. Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. Eur J Pharmacol 2011, 673(1-3):56-64.
16. Hirano T., Abe K., Gotoh M., Oka K. Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Br J Cancer 1995, 72(6):1380-1388.
17. Datla K.P., Christidou M., Widmer W.W., Rooprai H.K., Dexter D.T. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport 2001, 12(17):3871-3875.
18. Lake B.G., Beamand J.A., Tredger J.M., Barton P.T., Renwick A.B., Price R.J. Inhibition of xenobiotic-induced genotoxicity in cultured precision-cut human and rat liver slices. Mutat Res 1999, 440(1):91-100.
19. Lakshmi A., Subramanian S. Chemotherapeutic effect of tangeretin, a polymethoxylated flavone studied in 7, 12-dimethylbenz(a)anthracene induced mammary carcinoma in experimental rats. Biochimie 2014, 99:96-109.
20. Arun B., Udayachander M., Meenakshi A. 7,12-Dimethylbenzanthracene induced mammary tumours in Wistar rats by 'air pouch' technique-a new approach. Cancer Lett 1984, 25(2):187-194.
21. Geran R., Greenberg N., MacDonald M., Schumacher A., Abbott B. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972, 3:61-63.
22. Plucinsky M.C., Riley W.M., Prorok J.J., Alhadeff J.A. Total and lipid-associated serum sialic acid levels in cancer patients with different primary sites and differing degrees of metastatic involvement. Cancer 1986, 58:2680-2685.
23. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
24. van Bezooijen R.L., Que I., Ederveen A.G., Kloosterboer H.J., Papapoulos S.E., Löwik C.W. Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J Endocrinol 1998, 159(1):27-34.
25. Russo J., Gusterson B.A., Rogers A.E., Russo I.H., Wellings S.R., van Zwieten M.J. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990, 62(3):244-278.
26. Ploton D., Menager M., Jeannesson P., Himber G., Pigeon F., Adnet J.J. Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J 1986, 18(1):5-14.
27. Migliaccio A.R., Rana R.A., Sanchez M., Lorenzini R., Centurione L., Bianchi L., et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med 2003, 197(3):281-296.
28. Yamabayashi S. Periodic acid-Schiff-alcian blue: a method for the differential staining of glycoproteins. Histochem J 1987, 19(10-11):565-571.
29. Young B., Heath J.W. WHEATER'S functional histology: a text and colour atlas 2000, Churchill Livingstone, Philadelphia. 4th ed.
30. Glauert M., Lewis P.R. Biological specimen preparation for transmission electron microscopy. Practical methods in electron, microscopy 1998, 17.
31. Brown P.D., Levy A.T., Margulies I.M., Liotta L.A., Stetler-Stevenson W.G. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990, 50(19):6184-6191.
32. Andreeff M., Goodrich D.W., Pardee A.B. Cell proliferation, differentiation, and apoptosis. Holland-Frei cancer medicine 2000, BC Decker, Hamilton (ON), [Chapter 2]. 5th ed. R.C. Bast, D.W. Kufe, R.E. Pollock (Eds.).
33. Vanhoecke B.W., Delporte F., Van Braeckel E., Heyerick A., Depypere H.T., Nuytinck M., et al. A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In Vivo 2005, 19(1):103-107.
34. Walle T. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?. Semin Cancer Biol 2007, 17(5):354-362.
35. Walle T., Walle U.K. Novel methoxylated flavone inhibitors of cytochrome P450 1B1 in SCC-9 human oral cancer cells. J Pharm Pharmacol 2007, 59(6):857-862.
36. Mertani H.C., Garcia-Caballero T., Lambert A., Gérard F., Palayer C., Boutin J.M., et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998, 79(2):202-211.
37. Gregoraszczuk E.L., Milewicz T., Kolodziejczyk J., Krzysiek J., Basta A., Sztefko K., et al. Progesterone-induced secretion of growth hormone, insulin-like growth factor I and prolactin by human breast cancer explants. Gynecol Endocrinol 2001, 15(4):251-258.
38. el-Aziz M.A., Hassan H.A., Mohamed M.H., Meki A.R., Abdel-Ghaffar S.K., Hussein M.R. The biochemical and morphological alterations following administration of melatonin, retinoic acid and Nigella sativa in mammary carcinoma: an animal model. Int J Exp Pathol 2005, 86(6):383-396.
39. Sönmez H., Süer S., Güngör Z., Baloglu H., Kökoglu E. Tissue and serum sialidase levels in breast cancer. Cancer Lett 1999, 136(1):75-78.
40. Raval G.N., Patel D.D., Parekh L.J., Patel J.B., Shah M.H., Patel P.S. Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. Oral Dis 2003, 9(3):119-128.
41. Liou G.Y., Storz P. Reactive oxygen species in cancer. Free Radic Res 2010, 44(5):479-496.
42. Rossner P., Terry M.B., Gammon M.D., Agrawal M., Zhang F.F., Ferris J.S., et al. Plasma protein carbonyl levels and breast cancer risk. J Cell Mol Med 2007, 11(5):1138-1148.
43. Jang T.J., Kim D.K. Inducible nitric oxide synthase expression of tumor and stromal cells is associated with the progression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Cancer Lett 2002, 182(2):121-126.
44. Derenzini M., Ploton D. Interphase nucleolar organizer regions in cancer cells. Int Rev Exp Pathol 1991, 32:149-192.
45. Derenzini M., Pession A., Trerè D. Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab Invest 1990, 63(1):137-140.
46. Tomita M., Matsuzaki Y., Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg 2000, 69(6):1686-1690.
47. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999, 13(11):1382-1397.
48. Buijs J.T., Cleton A.M., Smit V.T., Löwik C.W., Papapoulos S E., Pluijm G.V. Prognostic significance of periodic acid-Schiff-positive patterns in primary breast cancer and its lymph node metastases. Breast Cancer Res Treat 2004, 84(2):117-130.
49. Ramos C.V., Taylor H.B. Lipid-rich carcinoma of the breast. A clinicopathologic analysis of 13 examples. Cancer 1974, 33(3):812-819.
50. Llaverias G., Danilo C., Mercier I., Daumer K., Capozza F., Williams T.M., et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011, 178(1):402-412.
51. Beckonert O., Monnerjahn J., Bonk U., Leibfritz D. Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed 2003, 16(1):1-11.
52. Leonardi E., Girlando S., Serio G., Mauri F.A., Perrone G., Scampini S., et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992, 45(5):416-419.
53. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12(12):1063-1073.
54. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56(4):549-580.
55. Indinnimeo M., Cicchini C., Stazi A., Limiti M.R., Ghini C., Mingazzini P., et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000, 19(4):471-475.
56. Ishida S., Huang E., Zuzan H., Spang R., Leone G., West M., et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001, 21(14):4684-4699.
57. Lu X., Ji Jung, Cho H.J., Lim D.Y., Lee H.S., Chun H.S., et al. Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 2005, 135(12):2884-2890.
58. Khan A.R., James M.N. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci 1998, 7(4):815-836.
59. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25(1):9-34.
60. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.